Drug Class Description
Vitamins (vitamin C, B vitamins).

Generic Name
Vitamins B & C

Drug Description
Pabrinex Intramuscular High Potency

Presentation
Injection for intramuscular use: two (5ml, 2ml) amber glass ampoules containing sterile aqueous solutions which are to be mixed prior to administration.

Indications
Rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C, particularly in alcoholism, after acute infections, post-operatively and in psychiatric states.

Adult Dosage
Pabrinex is also available as an Intravenous High Potency Injection. The contents of one ampoule number 1 and one ampoule number 2 of Pabrinex Intramuscular High Potency (total 7ml) are drawn up into a syringe to mix them just before use, then injected slowly high into the gluteal muscle, 5cm below the iliac crest.Adults: The contents of one pair of ampoules (7ml) twice daily for up to 7 days.Children: Pabrinex Intramuscular High Potency is rarely indicated for administration to children, however suitable doses are as follows:Under 6 yearsone quarter of the adult dose6-10 yearsone third of the adult dose10-12 yearsone half to two thirds of the adult dose14 years and overas for the adult dose

Contra Indications
Known hypersensitivity to any of the active constituents.

Special Precautions
Repeated injections of preparations containing high concentrations of vitamin B1 (thiamine) may give rise to anaphylactic shock. Mild allergic reactions such as sneezing or mild asthma are warning signs that further injections may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex Intramuscular High Potency is administered.Not for intravenous use.

Interactions
The content of pyridoxine may interfere with the effects of concurrent levodopa therapy.

Adverse Reactions
Occasionally, hypotension and mild paraesthesia from continued high doses of thiamine; occasionally mild ache at local site of injection.

Manufacturer
Archimedes Pharma UK Ltd

Drug Availability
(POM)

Updated
19 June 2009